The Medical Advisor

Medically Reviewed by: OneDayMD Editorial Team Last Updated: April 2026 In September 2024, a first-of-its-kind protocol utilizing ivermectin, fenbendazole, and mebendazole for cancer treatment was peer-reviewed and officially published in the Journal of Orthomolecular Medicine . Led by researchers Dr. Ilyes Baghli, Dr. Pierrick Martinez, and FLCCC's Dr. Paul Marik, the protocol applies antiparasitic drugs — originally developed to combat parasites — to cancer treatment, building on emerging preclinical and clinical evidence of their anticancer properties. This trio of repurposed drugs has been shown to disrupt the growth of cancer cells, particularly by targeting microtubules, the essential structures that allow cancer to multiply uncontrollably. What makes this protocol even more potent is the synergistic effect when these drugs are used together, creating a powerful new affordable weapon against cancer. Journal of Orthomolecular Medicine 2024 Targeting the Mitochondrial-Stem Cel...

Nicolas Hulscher and colleagues conducted a survey of 197 Cancer patients taking Ivermectin and Mebendazole for 6 months (abstract below) and confirmed: 84.4% reported a clinical benefit  32.8% reported No evidence of disease  15.6% reported tumor regression The study began with 197 cancer patients, and 122 completed follow-up. Patients were prescribed capsules containing 25 mg ivermectin and 250 mg mebendazole. They took up to 4 capsules per day according to physician’s recommendation. Self-reported cancer outcomes at 6-month follow-up (N=122) Real-World Clinical Outcomes of Ivermectin and Mebendazole in Cancer Patients: Results from a Prospective Observational Cohort (2026) Abstract Background: Drug repurposing offers a pathway to identify accessible, low-toxicity cancer therapies. Ivermectin and mebendazole have demonstrated multi-target anti-cancer activity in preclinical models, including the inhibition of cancer cell proliferation and the targeting of cancer stem cells. ...

If you trying to understand and looking for evidence about time-restricted eating, you've come to the right place. Time-restricted eating is just what it sounds like. It's a form of intermittent fasting where you eat all of your meals for the day within a restricted window of time, ranging from two to eight hours. That means you're avoiding food (fasting) for 16 to 22 consecutive hours. Eating within a four- to six-hour window is likely close to metabolic ideal for most. As noted in the paper "A Time to Fast," published in the November 2018 issue of Science : "Adjustment of meal size and frequency have emerged as powerful tools to ameliorate and postpone the onset of disease and delay aging, whereas periods of fasting, with or without energy intake, can have profound health benefits. The underlying physiological processes involve periodic shifts of metabolic fuel sources, promotion of repair mechanisms, and the optimization of energy utilization for cellular ...